Liposonix® Custom Contouring™ Treatment Now Available in U.S. and Canada: 1 Treatment, 1 Hour, 1 Size Smaller
HAYWARD, Calif., Jan. 11, 2012 /CNW/ - Today, Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic treatments, announced the arrival of its groundbreaking Liposonix technology in the United States and Canada. Using advanced high-intensity focused ultrasound (HIFU) technology, Liposonix is a non-surgical permanent fat reduction procedure that has been clinically shown to slim down the waistline by one pant or dress size without surgery or downtime. It is indicated for non-invasive waist circumference reduction for use on both the abdomen and love handles.
To view the multimedia assets, please click: http://www.multivu.com/mnr/54037-solta-liposonix-custom-contouring-waistline-fat-reduction
(Photo: http://photos.prnewswire.com/prnh/20120111/MM32412 )
"Liposonix is a significant scientific advance for people who want a safe, effective and convenient way to get rid of that last unwanted inch around the waist," said Anne Chapas, M.D., Assistant Clinical Professor at New York University School of Medicine and Founder and Medical Director of Union Square Laser Dermatology. "When diet and exercise just aren't enough to lose that last inch, the Liposonix custom contouring treatment is a terrific option for patients to achieve the shape they want without the expense, discomfort and recovery time of invasive procedures, such as liposuction." (See Dr. Chapas demonstrate Liposonix treatment on the Dr. Oz show.)
Unlike other non-invasive fat reduction treatments, Liposonix permanently destroys the fat cells found beneath the skin, without harming the skin, with just one treatment in a procedure that takes about one hour. The body naturally processes and removes the fat tissue over a period of 8 to 12 weeks, leaving behind the desired slimmer, more contoured waistline. Clinical studies have demonstrated an average waist circumference reduction of approximately 2.6 cm (1 inch) after a single Liposonix treatment.
"Liposonix technology was developed over a period of 10 years by leading scientists and ultrasound experts with more than 200 years of combined experience in the development of therapeutic and diagnostic ultrasound devices," said Grant Stevens, M.D., F.A.C.S, Associate Clinical Professor of Plastic Surgery USC Division of Plastic Surgery, Director of the USC-Marina del Rey Aesthetic Surgery Fellowship and Marina Plastic Surgery Associates. "I feel confident that I can now offer my patients an effective non-invasive treatment that specifically targets the stubborn fat in the abdomen and love handles that so many of my patients want to lose."
To quantify the extent of the desire to lose fat in the waist area, Solta Medical sponsored "The State of Love Handles in America" nationwide survey of more than 1,000 women. The just released survey findings reveal that:
- 62% of women say the part of their body they are most uncomfortable with is their tummy/love handles.
- 45% claim they would give up sex for one year to lose an inch.
- 66% would give up chocolate for one year to lose an inch.
- 75% would give up clothes shopping for one year to lose an inch.
The survey findings support a growing demand for fat reduction treatments. In fact, more than a half million fat reduction procedures were performed in the U.S. in 2011, and it is estimated that the non-invasive fat reduction market will grow by 42% annually through 2016 – nine times faster than its surgical counterparts.
"The addition of Liposonix to our brand portfolio allows us to expand into the fast-growing, non-invasive fat reduction market and to offer a new and exciting approach to custom body contouring," said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer of Solta. "We now have one of the strongest portfolios in the aesthetic space, with non-invasive, cutting-edge technologies in large and growing market segments – body contouring, skin tightening, skin resurfacing and rejuvenation, as well as acne treatment."
For more information on Liposonix, and to download the full results of the "State of the America's Love Handles Study," visit www.liposonix.com. You can also visit the Liposonix Facebook page.
ABOUT SOLTA MEDICAL, INC.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of issues under the industry's six premier brands: Thermage®, Fraxel®, Isolaz®, CLARO®, Clear + Brilliant® and Liposonix®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Clear + Brilliant is a unique, cost-effective treatment that utilizes safe, fractional laser technology to correct and prevent early signs of aging. Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
© 2010 Solta Medical, Inc. All rights reserved. Thermage, Fraxel, Isolaz, Clear + Brilliant, CLARO, Liposonix and Solta Medical are trademarks or registered trademarks of Solta Medical, Inc. or its subsidiaries.
 Millennium Research Group, Inc. US Markets for Body Contouring Devices 2012.
SOURCE Solta Medical, Inc.
For further information:
Jennifer Hacker, Media Relations, Cohn & Wolfe, +1-404-260-3509, firstname.lastname@example.org
PRN Photo Desk, email@example.com